Just to clear up any confusion I caused with the erroneous analysis (for anyone who cares!). The calculation of MACE benefit for apabetalone depends on the proportion of MACE (not patients) in each patient group.  In the renal substudy analysis of the dataset, the CKD patients got a 50% benefit and accounted for about 25% of MACE whereas the nonCKD patients got 6% benefit and accounted for the remaining 75% of MACE:

(0.5 x 0.25) + (0.06 x 0.75) = 0.17

In the LDL substudy analysis of the dataset, the low LDL patients got a 40% benefit and accounted for about 45% of MACE whereas the high LDL patients got 0% benefit and accounted for the remaining 55% of MACE:

(0.4 x 0.45) + (0 x 0.55) = 0.18.

Close enough for rough calculations.  Both analyses support the overall reduction in MACE of 18% that has been reported for the trial.  Nothing to reconcile except my earlier congnitive impairment.  Bring on CTAD!

Jupe